Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327182 | 1.00 | PRCP (0.58) | PRCPGAASLC22A1RECQLTSHR | |
| Hydrochloric Acid SCHEMBL28282197 | 0.98 | GAA (0.59) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL9587010 | 0.79 | PRCP (0.58) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL30218848 | 0.79 | PRCP (0.53) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL1011425 | 0.79 | PRCP (0.53) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL24017043 | 0.78 | PRCP (0.70) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL1566232 | 0.78 | PNMT (0.42) | PRCPMAPT | |
| SCHEMBL16799768 | 0.78 | PRCP (0.70) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL30368634 | 0.78 | PRCP (0.70) | PRCPGAASLC22A1RECQLTSHR | |
| Hydrochloric Acid SCHEMBL1124323 | 0.77 | GAA (0.54) | PRCPGAASLC22A1RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | PRCP 1601/4885GAA 73/4885SLC22A1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.